logo
You'd Need To Work for 3.5 Million Years To Match Elon Musk's Net Worth — Here's the Math

You'd Need To Work for 3.5 Million Years To Match Elon Musk's Net Worth — Here's the Math

Yahoo24-07-2025
Elon Musk has been in the news quite a bit lately, and his venture into politics has put his net worth on a yo-yo string. However, Musk remains the world's richest person: As of early July 2025, his net worth was $403.4 billion.
Find Out:
Read Next:
That number is astronomically large and may be difficult to wrap your head around. Someone making around $115,000 annually, or $55 per hour, would need to work 3.5 million years to accumulate that amount of money. Here are some other salaries and how long you'd need to work with them to catch up to Musk.
Minimum Wage
In the U.S., the federal minimum wage is $7.25 per hour. While the minimum wage can be higher throughout the country, states like Texas, Indiana and Wisconsin stick to the federal minimum. If you work a minimum wage job in one of those states, don't owe any taxes and could save 100% of your income, you'd need to work 55.6 billion hours to become as rich as Musk. Taking into account that most people work 40 hours a week, it would take 26.7 million years of full-time work.
Washington currently pays out the highest minimum wage to employees at $16.66 per hour. While this is quite a leap from the federal minimum wage, it would still take 11.6 million years to reach Musk's net worth.
Learn More:
Salaries at Musk's Companies
Musk owns various high-profile companies, which employ some of the brightest minds in the world. While many of his employees receive high salaries, none of them are close to reaching Musk's net worth anytime soon.
Process Technician at SpaceX
SpaceX, which designs, makes and launches rockets, has been vocal about its mission to reach Mars. However, getting there involves a lot of coordination between different roles, such as process technicians. Process technicians monitor the industrial processes of a company to make sure they're efficient and safe. At SpaceX, the average process technician's salary is $67,400 per year, so to reach Musk's level, they would need to work for about 6 million years.
Software Engineer at X
On Oct. 28, 2022, Musk completed his purchase of Twitter for $44 billion and began transforming the social media platform into X. As of 2025, a software engineer working at X in the U.S. makes $147,524 annually. This is considered an excellent salary by many, but it would still take a considerable amount of time for someone in this position to catch up to Musk: Dividing Musk's net worth by $147,524 amounts to 2.7 million years.
CFO at Tesla
The chief financial officer oversees a business' financial health, determining its strategies, forecasting and managing its cash flow. Because their role is so crucial to the success of the company, they typically receive high salaries. Currently, Tesla's CFO is Vaibhav Taneja, and in 2024, he earned $139 million. What Taneja made in just a year is much more than most people will make in their lifetime. However, even Taneja would need to keep up this high salary for 2,903 years to be as wealthy as Musk.
More From GOBankingRates
3 Luxury SUVs That Will Have Massive Price Drops in Summer 2025
How Much Money Is Needed To Be Considered Middle Class in Your State?
5 Cities You Need To Consider If You're Retiring in 2025
This article originally appeared on GOBankingRates.com: You'd Need To Work for 3.5 Million Years To Match Elon Musk's Net Worth — Here's the Math
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Respiree Secures Second FDA 510(k) Clearance, Expands Cardio-Respiratory Wearable to Home Use via 1Bio™ Connected Care Platform
Respiree Secures Second FDA 510(k) Clearance, Expands Cardio-Respiratory Wearable to Home Use via 1Bio™ Connected Care Platform

Yahoo

time8 minutes ago

  • Yahoo

Respiree Secures Second FDA 510(k) Clearance, Expands Cardio-Respiratory Wearable to Home Use via 1Bio™ Connected Care Platform

HOUSTON and SINGAPORE, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Respiree, a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the healthcare continuum, today announced it has received its second U.S. Food and Drug Administration (FDA) 510(k) clearance. The clearance expands the use of its RS001 cardio-respiratory wearable to home environments and includes approval for its connected care platform marketed as 1Bio™. Illustrative Image of Respiree's RS001 Wearable With its Connected Care 1Bio™ Platform The RS001 is a chest-worn device that directly measures respiration and offers passive cardio-respiratory monitoring. Originally cleared for in-patient clinical use, the RS001's use in home settings marks a significant step toward more accessible and preventive healthcare. The device connects to a cellular hub, which enables data to be visualized in real time via the connected care 1Bio™ dashboard. 'Respiration is the most predictive vital sign for clinical deterioration, yet it remains underutilized – particularly outside hospital settings,' said Dr. Gurpreet Singh, CEO and Founder of Respiree. 'This FDA 510(k) extension allows healthcare systems to passively and accurately monitor leading indicators in the home, enabling earlier interventions and reducing the overall burden on healthcare infrastructure.' The announcement follows Respiree's recent US$11.6 million Series A financing round, led by We Venture Capital and ClavystBio, which will accelerate development toward potential regulatory approvals and global market expansion. Respiree also announced plans to pursue additional FDA clearances for its proprietary AI software, aiming to integrate artificial intelligence models into the 1Bio™ platform for both inpatient and home-based care. 'These are exciting times for us,' added Dr. Singh. 'Our first 510(k) was for the wearable; this second one is for the platform. We are now focused on bringing our flagship AI models into the fold as a Software as a Medical Device (SaMD).' About Respiree Respiree™ is an AI/ML health tech company building state-of-the-art clinically-validated artificial intelligence (AI) for managing disease progression across healthcare's care continuum. The 1Bio™ platform by Respiree™ uses data from the EHR and its proprietary US-patented and FDA-cleared sensors to longitudinal measure and track disease progression. Respiree™ is now available in U.S., Australia and Asia-Pacific (APAC). Respiree™ is CE marked, has received regulatory clearances in Australia from the Therapeutics Goods Administration and has received the 510k clearance from the United States Food and Drug Administration (FDA). ( Media Enquiries Evangeline FuAdministrative ManagerRespiree Pte LtdEmail: evangeline@ A photo accompanying this announcement is available at in to access your portfolio

Praxis Precision Medicines to Participate in Upcoming Fireside Chat
Praxis Precision Medicines to Participate in Upcoming Fireside Chat

Yahoo

time8 minutes ago

  • Yahoo

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Piper Sandler senior research analyst Yasmin Rahini on August 7, 2025 at 11:00amEST. The event will be webcast live and the registration link can be found here. About Praxis Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit and follow us on Facebook, Instagram, LinkedIn and Twitter/X. CONTACT: Investor Contact: Praxis Precision Medicines investors@ 857-702-9452 Media Contact: Dan Ferry Life Science Advisors Daniel@ 617-430-7576Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Lender Itau hikes net interest income outlook as profit edges above forecasts
Lender Itau hikes net interest income outlook as profit edges above forecasts

Yahoo

time8 minutes ago

  • Yahoo

Lender Itau hikes net interest income outlook as profit edges above forecasts

SAO PAULO (Reuters) -Brazilian lender Itau Unibanco on Tuesday posted a 14.3% rise in second-quarter net recurring profit from a year earlier, slightly beating estimates while also upping its yearly projection for the growth of net interest income with clients. Itau, Latin America's most valuable bank by market value, reported an 11.5 billion reais ($2.09 billion) net recurring profit for the quarter through the end of June, compared to an estimate of 11.3 billion reais from analysts polled by LSEG. The Brazilian lender's annualized return on equity (ROE), a gauge of profitability, stood at 23.3%, rising from 22.4% a year earlier. The lender said it expects the net interest income (NII) with clients to grow between 11% and 14% this year, from 7.5% to 11.5% previously. Itau also revised the effective tax rate to between 28.5% and 30.5% this year, from a range between 27% and 29% previously. In a separate filing, Itau announced interest on equity to shareholders of about 0.36 real per share. ($1 = 5.5043 reais) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store